Search clinical trials for: SHR-1210+Apatinib

Total 4845 results

Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Neoplasm Malignant | Tumor, Solid | Cancer, Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy

Australia
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Hepatocellular Carcinoma

China
Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR-1210 BE Study on Healthy Subjects

Advanced Tumors

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Hepatocellular Carcinoma | Gastric Cancer

China
Sun Yat-sen University

Completed

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Metastatic Cervical Cancer

China
Beijing Hospital
Chinese Society of Clinical Oncology

Recruiting

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Solid Tumor

China
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Resectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (HCC-009)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Guangdong Association of Clinical Trials

Not yet recruiting

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Non-small Cell Lung Cancer
Beijing Sanbo Brain Hospital

Recruiting

Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Primary Central Nervous System Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Lung Neoplasms

China
Guangdong Association of Clinical Trials

Unknown

Efficacy and Safety of Camrelizumab in Real-World Study

Non-small Cell Lung Cancer

China
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Solid Tumor

China
Yanqiao Zhang

Not yet recruiting

A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）

Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Breast Cancer

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)

Toxicity | Overall Survival | Progression-free Survival | Clinical Benefit Rate

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Non-Small-Cell Lung Cancer

China
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Feng Wang

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NSCLC
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Hepatocellular Carcinoma Non-Resectable

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Hodgkin Lymphoma, Adult

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Bronchogenic | Lung Disease | Respiratory Tract Disease | Respiratory Tract Neoplasms Nec | Neoplasm, Bronchial

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Advanced Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Advanced Biliary Tract Carcinoma | Advanced Primary Liver Cancer

China
Peking Union Medical College Hospital

Unknown

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Nasopharyngeal Carcinoma

China
Hangzhou Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Esophageal Neoplasms | Esophageal Diseases | Esophageal Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Advanced Solid Tumors

China
Junling Li

Recruiting

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Advanced Non Squamous NSCLC

China

Search clinical trials for: SHR-1210+Apatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations